Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a health advocate prevent organ rejection in kids after liver transplant?

NCT ID NCT07279350

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 11, 2026 · Updated 3 times

Summary

This study tests whether a health advocate can help families of children who recently had a liver transplant. The advocate works with the family for 90 days to find resources, coordinate appointments, and communicate concerns to the medical team. The goal is to see if this support reduces organ rejection and improves outcomes. About 108 families will take part, with half receiving the advocate and half getting a resource handout.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
health advocate (behavioural intervention)
What this could lead to
If it works, this could show that a health advocate helps families manage care after a child's liver transplant, potentially reducing organ rejection and improving long-term health.
What could go wrong
This is a small, early-stage trial with only 108 participants, so results may not apply to everyone. The intervention is short (90 days) and may not have lasting effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 108 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Aug 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

0 to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient \<18 years old at the time of liver transplant * Received a liver transplant within past 90 days * Family endorses material economic hardship on 10-questions Accountable Healthcare Communities screening tool. * Will receive follow-up care for at least 2 years * Family can read or write English or Spanish * A Legally Authorized Representative (LAR) can provide consent, and for children (12-17 years of age, the child is willing/able to provide assent.) * Family has a working phone and smartphone device capable of receiving calls or virtual visits via Zoom. Exclusion Criteria: * Patient has severe cognitive impairment. * 18 years of age or older at the time of consent * Patient unwilling or unable to consent/participate * Patient is a ward of the state (e.g. foster care) since present circumstances may not be reflective of child's past or future circumstances. * Non-English, non-Spanish speakers as ICFs, HIPAA authorization form, surveys, and interviews will only be available in these 2 languages. Languages besides English and Spanish are excluded from this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pediatric liver transplanted recipients are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of California, San Francisco

    RECRUITING

    San Francisco, California, 94158, United States

  • University of Pittsburgh Medical Center | Children Hospital of Pittsburgh

    RECRUITING

    Pittsburgh, Pennsylvania, 15224, United States